Myasthenia Gravis Treatment

Global Myasthenia Gravis Treatment Market to Reach US$2.7 Billion by 2030

The global market for Myasthenia Gravis Treatment estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Medication, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Surgery segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$481.6 Million While China is Forecast to Grow at 9.5% CAGR

The Myasthenia Gravis Treatment market in the U.S. is estimated at US$481.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$615.4 Million by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Myasthenia Gravis Treatment Market - Key Trends and Drivers Summarized

How Is the Market for Myasthenia Gravis Treatment Evolving?

The market for Myasthenia Gravis (MG) treatment is experiencing a phase of dynamic growth, driven by increasing awareness, a growing patient population, and advancements in medical therapies. MG is a rare autoimmune neuromuscular disorder characterized by muscle weakness and fatigue due to the immune system attacking acetylcholine receptors in the neuromuscular junction. Treatment for MG is primarily focused on managing symptoms and improving patients` quality of life. Current therapeutic options include cholinesterase inhibitors, corticosteroids, immunosuppressants, monoclonal antibodies, and plasmapheresis. While there is no known cure for MG, new developments in treatment options are aimed at extending remission periods and reducing the disease`s impact on daily life.

What Are the Latest Trends in Myasthenia Gravis Treatment?

Emerging treatment trends in MG are centered around novel therapeutics, such as biologics and targeted therapies, which offer more specific and efficient disease management. Monoclonal antibodies like eculizumab, approved by the U.S. FDA for MG, are gaining traction due to their efficacy in reducing symptoms and minimizing the need for other immunosuppressive drugs. Additionally, research is ongoing for therapies that target B-cell depletion and complement inhibition pathways, as these are believed to play significant roles in the autoimmune response underlying MG. The rise of personalized medicine is also influencing treatment strategies, with a focus on tailoring therapies based on individual patient profiles.

What Segments Are Driving Market Expansion?

Based on drug class, cholinesterase inhibitors and corticosteroids currently dominate the market; however, immunosuppressants and monoclonal antibodies are projected to witness rapid growth due to ongoing clinical trials and their increasing use in managing severe cases. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies accounting for the largest market share due to the specialized nature of MG treatments. Geographically, North America leads the market owing to the higher prevalence of MG, a robust healthcare infrastructure, and favorable reimbursement policies. The Asia-Pacific region, however, is expected to see significant growth as awareness and diagnosis rates increase.

What Factors Are Driving the Growth in the Myasthenia Gravis Treatment Market?

The growth in the Myasthenia Gravis treatment market is driven by several factors, including increasing prevalence, advancements in drug development, and rising awareness about the disease. The growing number of clinical trials and regulatory approvals for innovative therapies, such as monoclonal antibodies and other biologics, are expanding the treatment landscape. Efforts to enhance early diagnosis and intervention are improving patient outcomes, thereby driving demand for various therapeutic options. Furthermore, the introduction of new formulations that offer improved efficacy and fewer side effects is encouraging the adoption of advanced treatments. Investments in research and development, coupled with strategic collaborations among pharmaceutical companies, are also contributing to market expansion.

SCOPE OF STUDY:

The report analyzes the Myasthenia Gravis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Treatment Type (Medication, Surgery, Other Treatment Types); End-Use (Hospitals, Clinics, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie Inc.
• Alexion Pharmaceutical Inc.
• Avadel Pharmaceuticals plc
• Bausch Health Companies Inc.
• Baxter International, Inc.
• CSL Behring
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Grifols SA
• Novartis AG
• Pfizer, Inc.
• Shire plc
• Takeda Pharmaceutical Company Limited
• Valeant Pharmaceuticals International, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.